General
Preferred name
lobeglitazone
Synonyms
Lobeglitazone sulfate ()
CKD-501 ()
P&D ID
PD009007
CAS
607723-33-1
Tags
available
drug candidate
drug
Approved by
KFDA
First approval
2013
Drug indication
Type-2 diabetes
Drug Status
experimental
investigational
approved
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
It has been reported that the combined extent of the excretion of lobeglitazone to the bile, urine and intestine is low (less than 10% of total dose), suggesting that the; major route of elimination for the drug involves its metabolism [A19749].
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
ChEMBL Drugs
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
480.15
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
3
cLogP
3.69
TPSA
102.88
Fraction CSP3
0.25
Chiral centers
1.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
